Each enteric film-coated tablet contains: Serratiopeptidase 10 mg (20,000 Serratiopeptidase units).
Pharmacotherapeutic Group: A protease with anti-inflammatory activity.
Pharmacology: Serratiopeptidase improves aggravated circulation in the inflammatory focus by breaking down abnormal exudates and protein and by promoting the absorption of the decomposed products through the blood and lymphatic vessels. It also accelerates the elimination of sputum, pus and haematoma by breaking down the liquifying mucus secretions and fibrin clots. Another major useful action being increased concentration of antibiotics in the focus of infection.
Pharmacokinetics: Serratiopeptidase is absorbed orally as an intact molecule. Some amount of the orally administered Serratiopeptidase is transferred to blood stream in a catalytically active form. Significant amounts are absorbed through the lymphatic channels. In the blood Serratiopeptidase is complexed by α2-macroglobulin as an inclusion complex which leaves the active sites accessible.
It is known to penetrate into inflamed tissue but the time frames for the action are not known.
Serratiopeptidase is indicated for the following conditions: Inflammation associated with surgery, trauma, acute and chronic sinusitis, tonsillectomy, otitis media; breast engorgement; periodontitis, alveolar abscess, pericoronitis of wisdom tooth; lateral episiotomy, perineal laceration, salpingitis, cystitis, epididymitis, urethritis; incomplete expectoration of sputum in bronchitis, pulmonary tuberculosis, bronchial asthma, after anaesthesia.
Serratiopeptidase is widely used in a variety of lung conditions.
The recommended dose for Serratiopeptidase is 5 to 10 mg three times a day depending on the age. The tablets are enteric coated and should be swallowed whole after a meal.
No instances of overdosage with Serratiopeptidase have been reported. Disturbances in coagulation may occur and should be treated appropriately.
There are no known contraindications to Serratiopeptidase.
Serratiopeptidase should be given with caution to patients with coagulation abnormalities, severe hepatic or renal impairment, or those under treatment with anticoagulants. Patients should be under careful observation.
Generally, Serratiopeptidase is well tolerated. Occasionally it may cause gastro-intestinal effects such as anorexia, gastric discomfort and nausea.
Hypersensitivity reactions may occur rarely.
No drug interactions have been reported nor are there any reports of interference with any diagnostic tests.
M09AB - Enzymes ; Used in the treatment of musculo-skeletal disorders.
Enteric FC tab 10 mg 10 x 10's.
Sign Out
